With that staying reported, with no human trials there isn't a way to actually assess just how much YK11 can inhibit Myostatin in human beings (if at all), and if there is a dosage which could equate to the identical level of Myostatin inhibition that a genetic anomaly which has a gene mutation has.YK11 differs from classic SARMs like LGD-4033 and